











































RNA pull-down-Confocal Nanoscanning (RP-CONA) detects
quercetin as pri-miR-7/HuR interaction inhibitor that decreases -
Synuclein levels
Citation for published version:
Zhu, S, Roy Choudhury, N, Rooney, S, Pham, N, Koszela, J, Kelly, D, Spanos, C, Rappsilber, J, Auer, M &
Michlewski, G 2021, 'RNA pull-down-Confocal Nanoscanning (RP-CONA) detects quercetin as pri-miR-
7/HuR interaction inhibitor that decreases -Synuclein levels', Nucleic Acids Research.
https://doi.org/10.1093/nar/gkab484
Digital Object Identifier (DOI):
10.1093/nar/gkab484
Link:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Dec. 2021
1
RNA Pull-Down Confocal Nanoscanning (RP-CONA) detects quercetin as pri-miR-7/HuR 
interaction inhibitor that decreases -Synuclein levels
Siran Zhu1,2, Nila Roy Choudhury1, Saul Rooney1, Nhan T. Pham3, Joanna Koszela3, David Kelly4, 
Christos Spanos4, Juri Rappsilber4,5, Manfred Auer3, Gracjan Michlewski2,1,6
1Infection Medicine, University of Edinburgh, The Chancellor’s Building, Edinburgh, United 
Kingdom; 2Dioscuri Centre for RNA-Protein Interactions in Human Health and Disease, International 
Institute of Molecular and Cell Biology in Warsaw, Warsaw, Poland.3School of Biological Sciences, 
IQB3, University of Edinburgh, 4The Wellcome Centre for Cell Biology, University of Edinburgh, 
Michael Swann Building, Max Born Crescent, Edinburgh, United Kingdom, 5Department of 
Biotechnology, Technische Universität Berlin, Berlin, Germany, 6Zhejiang University-University of 
Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, Zhejiang, 
P.R. China, 
Correspondence should be addressed to G.M. (gmichlewski@iimcb.gov.pl)
Running Title: RP-CONA detects pri-miR-7/HuR inhibitors
Keywords: RP-CONA, miR-7, HuR, α-Synuclein, Parkinson’s disease

































































RNA-protein interactions are central to all gene expression processes and contribute to a variety of 
human diseases. Therapeutic approaches targeting RNA-protein interactions have shown promising 
effects on some diseases that are previously regarded as ‘incurable’. Here we developed a fluorescent 
on-bead screening platform: RNA Pull-Down COnfocal NAnoscanning (RP-CONA), to identify 
RNA-protein interaction modulators in eukaryotic cell extracts. Using RP-CONA, we identified small 
molecules that disrupt the interaction between HuR, an inhibitor of brain-enriched miR-7 biogenesis, 
and the conserved terminal loop of pri-miR-7-1. Importantly, miR-7’s primary target is an mRNA of 
α-Synuclein, which contributes to the aetiology of Parkinson’s disease. Our method identified a 
natural product quercetin as a molecule able to upregulate cellular miR-7 levels and downregulate the 
expression of α-Synuclein. This opens up new therapeutic avenues towards treatment of Parkinson’s 
disease as well as provides a novel methodology to search for modulators of RNA-protein interaction. 

































































RNA-protein interactions coordinate the whole of RNA metabolism, including transcription, RNA 
processing, modification, translation and turnover (1). Dysregulated RNA metabolism can result in 
serious diseases including cancer (2) and neuropathological conditions (3). In recent years, therapies 
targeting RNA-protein interactions have shown promising results and some of them are already in 
clinical trials (4-6). Among many types of RNAs, short non-coding microRNAs (miRNAs, miRs), 
that regulate gene expression by imperfect base-pairing to mRNA, hold great potential both as 
biomarkers (7) and therapeutics (8) in multiple human pathologies. The hairpin containing transcripts, 
known as primary miRNAs (pri-miRNAs), are processed by the Microprocessor complex to become 
stem-loop precursor miRNAs (pre-miRNAs) (9-13). The intermediates are further cut by an RNase 
III enzyme DICER, generating miRNA duplexes (14,15). Only the final product, the single-stranded 
mature miRNAs together with the Argonaute proteins are functional regulators of gene expression 
(16).
Parkinson's disease (PD) is an incurable neurodegenerative disease that affects all ages but is most 
prevalent in the elderly population, with over 1% of those over the age of 60 suffering from this 
disease (17). One of the main causes behind PD is overproduction and aggregation of a protein called 
α-Synuclein (α-Syn), expressed from the SNCA gene in the brain cells of affected individuals (18-
21). There is a large body of evidence that decreasing the levels of α-Syn should be beneficial for PD 
patients, and several clinical trials are now focusing on α-Syn clearance with small molecules, 
antibodies or vaccines (22). Notably, miR-7 has been shown to target α-Syn production (23) and is 
significantly downregulated in the substantia nigra pars compacta (SNpc) of PD patients (24). MiR-
7 also targets other genes implicated in PD, including RelA, Sir2 or Nlrp3 (25). For these reasons, 
approaches for miR-7 replacement therapies have been put forward (26).
The biogenesis of miRNAs is tightly controlled through RNA-protein interactions (27-31). Our group 
has identified that an RNA binding protein (RBP) HuR specifically binds to the Conserved Terminal 
Loop (CTL) of primary miR-7-1 (pri-miR-7-1). By recruiting another RBP MSI2, HuR increases the 
rigidity of the pri-miR-7-1 stem loop, therefore, blocking Microprocessor cleavage and preventing 
production of mature miR-7 (32). HuR-mediated inhibition of miR-7 biogenesis was independently 
reported by Lebedeva et al. (33). We have also found that the monounsaturated fatty acid - oleic acid 
(OA), previously found to bind to MSI2 (34), can dissociate the HuR/MSI2 complex from pri-miR-
7-1 and facilitate the biogenesis of miR-7 (35). However, OA is not effective at micromolar 
concentrations, has poor bioavailability when tested in cells and is toxic in high concentrations (36). 
































































Thus, it is necessary to identify potent pri-miR-7-1/HuR inhibitors that will elevate miR-7 levels and 
lead to downregulation of its targets, including α-Syn, which could provide alternative solutions to 
PD therapy.
Here we developed a fluorescent on-bead screening assay based on RNA Pull-Down Confocal 
Nanoscanning (RP-CONA), to identify small molecules that modulate the strength of RNA-protein 
interactions. Our method uses an ultra-sensitive RNA-protein pull-down assay in cell extracts from 
human cultured cells (37) detecting RNA-protein complex modulators by confocal microscopy (38-
41). We have demonstrated that the method works for various RNA-protein complexes and screening 
platforms. By employing RP-CONA, we identified quercetin, a natural flavonoid and known inhibitor 
of HuR/TNF-α mRNA interaction (42), as the most potent pri-miR-7-1/HuR interaction inhibitor. 
Quercetin induces miR-7 level and inhibits α-Syn expression in an HuR-dependent fashion. In 
summary, in this study we introduce RP-CONA as a new assay technique for the identification of 
small molecule modulators of RNA-protein interactions. We identified novel inhibitors of HuR/RNA 
complexes and have discovered a validated hit compound towards attenuation of α-Syn levels in PD.


































































HeLa and HEK293T cells were maintained in DMEM (Dulbecco’s Modified Eagle Medium, Gibco) 
containing 10% foetal bovine serum (Gibco). Transfection was performed using LipofectamineTM 
2000 Transfection Reagent (Invitrogen) following the manufacturer’s instructions.
Chemicals
The in-house 54-compound library was kindly provided by Professor Neil Carragher (The University 
of Edinburgh), including FDA-approved drugs and natural products of well-established anti-cancer 
mechanisms. The concentrations of library compounds were varied from 0.1 to 10 mM according to 
their optimal effects in previous cell studies in the Carragher’s lab. Ro 08-2750 was purchased from 
R&D Systems. Oleic acid, quercetin, luteolin, genistein, dihydrotanshinone I (DHTS), CMLD-2, 
cetylpyridinium chloride (CPC) and gossypol were purchased from Sigma-Aldrich. All 9 reagents 
were dissolved in DMSO to prepare 20 mM stock solutions. 
Plasmid construction
Human genomic DNA was isolated from HeLa cells using a GenElute™ Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich). Target genes were PCR amplified from genomic DNA using Phusion® 
High-Fidelity DNA Polymerase (NEB) and propagated following the instructions of CloneJET PCR 
Cloning Kit (Thermo). The HuR open reading frame was inserted downstream from the mCherry 
gene between XhoI and EcoRI in a pJW99 plasmid. DNA segments encoding miRNA stem loop 
sequences were cloned into a pCG plasmid (32) between the XbaI and BamHI cleavage sites. The 3’-
UTR of human α-Syn mRNA gene was inserted into a psiCHECK-2 plasmid between the XhoI and 
NotI sites downstream the Renilla luciferase (Rluc) gene. Sequence confirmation was carried out in 
Edinburgh Genomics or GENEWIZ.
Mutagenesis PCR
Mutants of psiCHECK-2-α-Syn-3’UTR were generated using mutagenesis PCR, where the 
nucleotides in the 3rd position of the putative miRNA binding sites were mutated. Primers used for 
mutagenesis are as follows: miR-7_s1-F: accatcagcagtgattgaagt; miR-7_s1-R: agacttcgagatacactgtaaa; 
miR-7_s2-F: attaatgatactgtctaagaataatg; miR-7_s2-R: agacacctaaaaatcttataatatat; miR-7_s3-F: 
acccttaatatttatctgacggta; miR-7_s3-R: agaaacactttaaaggagaatttg. PCR reactions were run for 18 cycles 
using Phusion polymerase. The template plasmids were digested by DpnI (NEB) treatment at 37℃ 
for 1.5 hours, followed by T4 Polynucleotide Kinase (NEB) treatment at 37℃ for 1 hour. Blunt-end 
































































ligation was performed using T4 DNA Ligase (NEB) at 4℃ overnight. The ligation products were 
transformed and propagated in E. coli.
Western blot analysis
Cultured cells were harvested and resuspended in Roeder D (200 mg/ml glycerol, 100 mM KCl, 0.2 
mM EDTA, 100 mM Tris pH 8.0, 500 μM DTT and 200 μM PMSF). Cell lysis was carried out in a 
Bioruptor® Plus sonication device (Diagenode) for 10 min (low intensity settings, 30s on/off). 60 μg 
of proteins in cell lysates were separated on a NuPAGE™ 4-12% Bis-Tris Protein Gel (Invitrogen) 
and transferred onto a nitrocellulose membrane (GE) in a GENIE® blotter (Idea Scientific) at 12V 
for 1 h. The membrane was blocked with 1:10 Western Blocking Reagent (Roche) in TBST (20 mM 
Tris pH 7.5, 137 mM NaCl and 0.1% (v/v) Tween 20). Proteins were detected with the following 
primary antibodies in TBST containing 1:20 Western Blocking Reagent, including rabbit polyclonal 
anti-HuR (Millipore), rabbit polyclonal DHX9 antibody (Proteintech), monoclonal anti-α-tubulin 
antibody (Sigma-Aldrich) and purified mouse anti-α-Synuclein (BD Biosciences). Following three 
washes in TBST, the membrane was incubated in the horseradish peroxidase (HRP) conjugated 
secondary anti-rabbit or anti-mouse IgG antibodies (Cell Signalling Technology) and developed with 
chemiluminescent substrate (Thermo #34580). Quantification of western blot bands were carried out 
in Image Studio Lite Ver 5.2.
RNA quantification
Total RNA was isolated from cells or cell extracts following manufacture’s instruction of TRI 
Reagent™ Solution (Invitrogen) or TRI Reagent® LS (Sigma-Aldrich), respectively. To quantify 
miRNA levels, reverse transcription and quantitative real-time PCR (qRT-PCR) were performed with 
miScript II RT Kit and SYBR Green PCR Kit respectively (QIAGEN). To quantify α-Syn mRNA 
levels, the GoTaq® 1-Step RT-qPCR System (Promega) was used with the primers (F: 5’-
gttgtggctgctgctgagaaa; R: 5’-tccctccttggttttggagcctac). The qRT-PCR reactions were performed in a 
Roche LightCycler® 96 System.
Dual luciferase assays
Luciferase reporter assays were performed according to the manufacture’s instruction of Dual-
Luciferase® Reporter Assay System (Promega). 1.2×104 of HeLa cells were plated in a well of 96-
well plates. For each well, 30 ng of psiCHECK2-α-Syn-3’UTR were co-transfected with 16.7 ng of 
pCG-pri-miRNA or 50 ng pCDNA-HuR plasmids in HeLa cells. Cells were lysed 48 hours after 
transfection by Passive Lysis Buffer (Promega). The luminescence levels of firefly and Renilla 
































































luciferases were recorded by a PolarStar OPTIMA Multidetection Microplate Reader (BMG 
LABTECH). The mRNA levels of luciferases were determined by qRT-PCR with following primers 
(Renilla-F: ggaatgggtaagtccggcaa; Renilla-R: ccaagcggtgaggtacttgt; firefly-F: gaacagctctgggtctaccg; 
firefly-R: gggatgatctggttgccgaa).
Generation of gene knockout cells
To knock out HuR in HEK293T and HeLa cells, a pair of guide RNAs (5’-cgaagucuguucagcagcau 
and 5’-cuugggucauguucugaggg) targeting the exon2 of human HuR gene were designed. The Alt-R® 
CRISPR-Cas9 crRNAs and tracRNA were synthesized by IDT. 100 μM of each crRNA was mixed 
with 100 μM of tracRNA in 100 μl duplex buffer (IDT) at 95℃ for 5 min, to form two crRNA-
tracRNA duplexes. HEK293T or HeLa cells were seeded in a 24-well plate. 1.5 μl of each duplex 
were co-transfected with 1 μl of GeneArt™ CRISPR Nuclease mRNA (Invitrogen). The cells were 
diluted and aliquoted to 96-well plates to make less than 1 cell count per well and lysed by 30 μl of 
Passive Lysis Buffer (Promega) when confluent. 2 μl of the cell extracts were loaded onto 
nitrocellulose membranes and tested against HuR and DHX9 antibodies. Cells showing HuR negative 
and DHX9 positive were selected and confirmed using western blot analysis. The genomic DNA of 
the knockouts were extracted and fragments covering the expected HuR knockout sites were PCR 
amplified using the forward primer (5’-gccctggacagtacactcgcc) and reverse primer (5’-
ccacatggccgaagactgca). After ligating into the cloning vector using the CloneJET PCR Cloning Kit 
(Thermo), the DNA fragments were sequenced, and the mutations were identified.
To knock out pri-miR-7-1 in HeLa cells, a pair of guide RNAs (5’-acauucaauacuaaucuugc and 5’-
accaaucauuuguccuguag) were designed flanking the stem loop sequence of human pri-miR-7-1 gene. 
Transfection of the CRISPR-Cas9 system was carried out as described before. Crude DNA was 
extracted by dissolving cells in solution 1 (25 mM NaOH, 0.2 mM EDTA) at 98℃ for 1 hour, and 
terminated by equal volume of solution 2 (40 mM Tris-HCL pH5.5). PCR was performed with 
primers flanking the targeted region (F: 5’-ctgcagaacaggtcagtttaagtt, R: 5’-tgcagaacacctatgaagcaga). 
The PCR products were visualised on an agarose gel and cells generating band shifts were selected. 
The miR-7 levels were tested by qRT-PCR. Sequences were determined using PCR products 
amplified from purified genomic DNAs of putative pri-miR-7-1 knockouts.
RP-CONA
Ni-NTA agarose beads (Qiagen, 30250) were sieved using 100 μm cell strainers (Corning, 431752) 
and 120 μm pore size filters (Millipore, NY2H04700) to obtain a uniform bead size population. The 
sieved beads were washed with binding buffer (0.3 M NaCl, 20 mM HEPES pH 7.5, 0.01% Triton 
































































X-100) and resuspended to 10% slurry. For each reaction, 150 pmol of 6×His-streptavidin 
(ProteoGenix) was mixed with 5 μl of sieved beads (10%) in a total volume of 20 μl binding buffer 
at 4℃, 1,000 rpm for 20 min. The biotinylated FITC-pri-miR-7-1-CTL (5’-FITC-
uguuguuuuuagauaacuaaaucgacaacaaa-Biotin-3’) were synthesized by IDT. 40 pmol of RNA was 
mixed with 5 μl of the streptavidin beads (10%) in a total volume of 20 μl PBS containing 0.01% 
Triton X-100 at 4℃, 1,000 rpm for 20 min. 
HuR KO-HEK293T cells were plated in a p150 dish and transfected with 40 μg of pJW99-HuR 
plasmids. The cell lysates were obtained 24 hours after transfection by sonication. The concentration 
of mCherry-HuR in the lysates was quantified following the instruction of an mCherry quantification 
kit (BioVision). The lysates containing 300 nM of mCherry-HuR were diluted in 20 μl of no glycerol-
Roeder D (100 mM KCL, 0.2 mM EDTA, 100 mM Tris pH 8.0, 0.5 mM DTT and 0.2 mM PMSF), 
and mixed with 30 μl of pulldown solution (1.5 mM MgCl2, 25 mM creatine-phosphate, 0.5 mM 
ATP, 0.25 μl Ribolock RNase Inhibitor (Invitrogen)) before loaded to a well of a black 384-well plate 
(SWISSCI or Greiner). 0.5 μl of compounds (dissolved in DMSO at 100 times of the final 
concentration) were added to the cell lysates and mixed vigorously at room temperature, 1,500 rpm 
for 20 min.
5 μl of FITC-pri-miR-7-CTL-beads (10%) was added to the treated lysates and mixed at room 
temperature, 1,500 rpm for 2 hours. Images were acquired in an Opera® High Content Screening 
System (PerkinElmer) or ImageXpress Micro Confocal (Molecular Devices) at 30 μm above well 
bottom, 20× magnification with air lenses. On the Opera HCS, three channels were detected: 
brightfield (690 nm diode at 70% power, 690/70 detection filter, 160 ms exposure time), FITC (488 
nm laser at 250 μW, 520/35 detection filter, 120 ms exposure time) and mCherry (561 nm laser at 
1250 μW, 600/40 detection filter, 240 ms exposure time). In ImageXpress, two channels were 
detected: FITC (FITC filter set: excitation 475/34, emission 536/40, exposure 25 ms) and mCherry 
(Texas Red filter set: excitation 560/32, emission 624/40, exposure 85 ms). FITC and mCherry rings 
were detected and the ring intensities were quantified in Image J, using a custom plugin 
(DOI:10.5281/ZENODO.4302193). Z’ factor was calculated using the equation Z’=1 – 3(SD positive 
control + SD negative control)/ |Mean positive control – Mean negative control| (43). 
Other RP-CONA assays were conducted in the same manner. All the RNAs were synthesized by IDT, 
including FITC-pri-miR-7-1/30a-TL-bio (5’-FITC-uguuguucugugaagccacagaugggacaacaaa-Biotin-
3’); Cy5-pre-let-7a-1-CTL-bio (5’-cy5-uuagggucacacccaccacugggagau-Biotin-3’); FITC-TNFα-
ARE-bio (5’-FITC-auuauuuauuauuuauuuauuauuua-Biotin-3’); and FITC-αSyn-ARE-bio (5’-FITC-
































































cuaaauccucacuauuuuuuuguugcug-Biotin-3’). Lin28-GFP was expressed using a pEGFP-N1 vector 
(44). Cy5 intensity was detected using Cy5 filter set (excitation 631/28, emission 692/40, exposure 2 
ms); and GFP using FITC filter set (exposure 100 ms). 
RNA pull-down assay 
RNA pull-down assay was carried out to detect binding of RNA-binding proteins, from whole cell 
extracts, to RNA immobilised on the beads. 500 pmol of pri-miR-7-1-CTL (5’-
uguuguuuuuagauaacuaaaucgacaacaaa) was treated with 100 mM NaAc and 5 mM sodium 
(meta)periodate in 200 μl of water and rotated for 1 hour at room temperature in the dark. The RNA 
was precipitated by adding 600 μl of 100% ethanol and 15 μl of 3 M NaAc in dry ice for 20 min, 
followed by centrifugation at 13,000 rpm, 4℃ for 10 min. The RNA pellet was washed with 70% 
ethanol and resuspended in 500 μl of 100 mM NaAc pH5. 200 μl of adipic acid dihydrazide-agarose 
(Sigma-Aldrich) were washed with 100 mM NaAc and mixed with 500 μl of the periodate oxidized 
pri-miR-7-1-CTL overnight at 4℃ in the dark. The pri-miR-7-1-CTL-beads were washed by 2M KCL, 
Buffer G (20 mM Tris-HCl pH 7.5, 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 
1.5 mM MgCl2, 1 mM DTT, and 200 μM PMSF) and Roeder D respectively. 
250 μl of HeLa cell lysates containing 1 mg of total protein were pre-incubated with 100 μM of test 
compounds and 400 μl of pulldown solution at 37℃, 700 rpm for 20 min. The pri-miR-7-1-CTL-
beads were incubated with the treated cell lysates, at 37℃, 1,200 rpm for 30 min. After washing with 
Buffer G, the beads were mixed with 6 μl of NuPAGE™ Sample Reducing Agent, 15 μl of LDS 
Sample Buffer and 39 μl of water. Proteins captured by RNA were denatured at 70 ℃, 1,000 rpm for 
10 min. 30 μl of the supernatant was loaded onto an SDS-PAGE gel and western blot was performed 
to detect the level of proteins. 
RNA immunoprecipitation (RIP) assay
HuR-bound pri-miR-7-1 and α-Syn  mRNA were immunoprecipitated following a method developed 
from a previously published protocol (45). In brief, 1.4×106 HuR-KO HeLa cells were plated in p100 
dishes, treated with DMSO or 20 μM quercetin, and transfected with 500 ng of pCDNA-HuR. 
RNA/proteins were cross-linked using 1% formaldehyde and incubated at room temperature for 10 
min with rocking. Crosslinking reactions were stopped by the addition of 0.25 M glycine (pH 7.0) 
followed by incubation at room temperature for 5 min. The cells were resuspended in 500 μl of RIPA 
buffer (50 mM Tris–Cl, pH 7.5, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.05% SDS, 
1 mM EDTA, 150 mM NaCl), sonicated and centrifuged to obtain cell lysates as described above. 
The protein levels were determined using the Pierce® BCA Protein Assay Kit (Thermo). 50 μl of 
































































Dynabeads™ Protein A for Immunoprecipitation (Invitrogen) were coupled with 3 μl of HuR 
antibody in BWB (0.02% Tween-20 in PBS) for 30 min at room temperature with rocking, then 
washed with RIPA buffer. The extracts containing 100 μg of protein were diluted with 500 μl of RIPA 
buffer, mixed with the antibody–coated beads at room temperature for 30 min. The beads were 
collected at 6000 g and the supernatant was kept for RNA extraction as loading control. The beads 
were washed five times with high-stringency RIPA buffer (50 mM Tris–Cl, pH 7.5, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 M NaCl, 4 M urea, and 0.2 mM PMSF). The beads 
containing the immunoprecipitated samples were collected and resuspended in 100 μl of 50 mM Tris–
Cl, pH 7.0, 5 mM EDTA, 10 mM dithiothreitol (DTT) and 1% SDS. The beads were then incubated 
at 70 °C for 45 min to reverse the crosslinking. The RNA was extracted from these samples using 
TRI Reagent® LS according to the manufacturers protocol. qRT-PCR was performed to detect pri-
miR-7-1 and α-Syn mRNA levels.
mRNA stability assay
1.44×105 WT or HuR KO HeLa cells were plated in 12-well plates, and treated with DMSO or 20 
µM of quercetin, together with 10 µg/ml actinomycin D (Sigma-Aldrich). The cells were collected at 
0, 6, or 12 hours after actinomycin D treatment. Total RNA was isolated using TRI ReagentTM. α-
Syn mRNA and 18S levels were quantified using qRT-PCR.

































































MiR-7 is a major inhibitor of α-Syn expression
MiR-7 and other miRs, such as miR-133b, miR-153, miR-34b or miR-34c, which also have the 
potential to target -Syn, have been shown to be downregulated in PD, thus allowing -Syn 
overproduction and accumulation (23,25,46-48). We collated all validated and predicted miRs 
targeting the 3’-UTR of α-Syn mRNA and cloned their pri-miR sequences into the pCG expression 
vector (Figure 1A). We used a dual luciferase reporter assay in HeLa cells with overexpression of 
individual miRs targeting α-Syn mRNA 3’-UTR coupled with Renilla luciferase mRNA. This assay 
showed that only miR-7 exhibited significant inhibition (>50%) of Renilla luciferase compared to 
other miRs, when equal amounts of pri-miR plasmids were transfected (Figure 1B). The upregulation 
of mature miR-7 was equal or less when compared with other miRs (Supplementary Figure 1A). 
Moreover, a single-nucleotide mutation in the previously identified miR-7 binding site (miR-7_s1) 
could desensitise α-Syn mRNA 3’-UTR to miR-7 overexpression, while other miR-7 binding sites 
(miR-7_s2 and miR-7_s3) did not present significant differences between the wildtype and mutated 
reporters (Figure 1C). Interestingly, mutations of miR-133b_s1 and miR-153_s1 sites exerted 
significant upregulation of expression from the α-Syn mRNA 3’-UTR Renilla luciferase construct, 
proving that miR-133b and miR-153 are involved in regulating -Syn levels, albeit to lesser extent 
and with more complex regulatory networks (Supplementary Figure 1B).
Importantly, a gradient of miR-7 overexpression exerted gradual and significant reduction of the 
expression of endogenous α-Syn in HeLa cells (Figure 1D, E), which is consistent with a previous 
publication (23). HeLa cells were chosen because according to Human Protein Atlas these cells have 
high basal levels of α-Syn transcripts when compared with most other cultured cells (49). Other miRs, 
exemplified by miR-153 and miR-133b, exerted no significant inhibitive effects on endogenous α-
Syn levels, in spite of their previously reported function as α-Syn inhibitors (Supplementary Figure 
1C) (50,51). In summary, we conclude that miR-7 is the most potent α-Syn suppressor and uses a 
well-defined target site on the α-Syn mRNA 3’-UTR.
RP-CONA: a novel, lysate-based scanning microscopy on-bead screening platform for small 
molecules that modulate RNA-protein complexes
Due to the supremacy of miR-7 in inhibiting the expression of α-Syn, it will be crucial to pursue 
therapeutic approaches for PD through the miR-7/α-Syn pathway. We hypothesize that as the 
































































biogenesis of pri-miR-7-1 is inhibited by HuR through an interaction with the Conserved Terminal 
Loop (CTL), small molecules that dissociate HuR from miR-7 CTL will facilitate the production of 
mature miR-7, which in turn will contribute to a reduction of α-Syn levels (32).
To identify pri-miR-7/HuR inhibitors, we developed a screening platform that combines techniques 
of RNA Pull-Down (RP) from eukaryotic cell extracts, and on-bead scanning confocal microscopy 
(CONA), given the name RP-CONA (Figure 2). First, we attached 5’FITC and 3’biotin-tagged pri-
miR-7-1-CTL to 6×His-Streptavidin Ni-NTA agarose beads. Then we used HuR KO HEK293T cells, 
generated with CRISPR-Cas9 targeting, to overexpress mCherry-HuR (Supplementary Figure 2A-
C). The HEK293T cells were chosen as they are known to support highly efficient recombinant 
protein production (52). Moreover, the HuR KO cells were used to avoid signal dilution from an 
untagged, endogenous HuR. Next, we performed RNA pull-down and imaged the fluorescently 
labelled RNA and mCherry-HuR on a confocal imaging system. Fluorescent rings/halos on the 
periphery of microbeads indicate binding events in separate detection channels. The amounts of 
bound RNA or protein were detected from fluorescence emission intensities of the rings/halos. Pri-
miR-7-1-CTL/mCherryHuR inhibitors are expected to attenuate mCherry ring intensities without 
affecting FITC levels.
We first tested the RP-CONA assay using the Opera HCS instrument. The preliminary results showed 
that RP-CONA generated FITC rings in the presence of the fluorescently tagged RNA, and mCherry 
rings only when mCherry-HuR was pulled down by pri-miR-7-1-CTL (Figure 3A, B). No overlapping 
signals were observed in different detection channels. The addition of an increasing concentration of 
untagged pri-miR-7-1-CTL competitively decreased mCherry signals (Figure 3C, D). Oleic acid, the 
known pri-miR-7-1/HuR complex inhibitor reduced mCherry ring intensities at high millimolar 
concentrations, as reported before (Figure 3E, F) (35). To show that RP-CONA can be run on various 
scanning instruments we then switched to another confocal image platform, the ImageXpress, which 
gave similar quality of images compared to Opera HCS (Supplementary Figure 3A, B). Moreover, 
the relative mCherry/FITC value was proportional to the concentration of mCherry-HuR 
(Supplementary Figure 3C-E). Importantly, if we replaced the CTL of pri-miR-7-1 with the non-
conserved Terminal Loop (TL) of pri-miR-30a that does not bind HuR (Figure 4A, B), or 
overexpressed mCherry instead of mCherry-HuR to make the cell extracts (Figure 4C), the mCherry 
rings were not observed. Moreover, the addition of polyclonal anti-HuR antibody to FITC-pri-miR-
7-1-CTL/mCherry-HuR complex significantly decreased the mCherry ring intensities, compared with 
the control anti-Lin28a antibody (Figure 4D, E). This evidence proves that RP-CONA is a sensitive 
and specific method to probe pri-miR-7-1-CTL/HuR interactions.
































































RP-CONA is also applicable for monitoring the interactions between other RNA-protein complexes, 
with different fluorophore pairs. To this end, we tested the well-established pre-let-7/Lin28a 
interaction (53-55) in RP-CONA, with the Cy5-tagged pre-let-7a-1-CTL and HEK293T cell extracts 
containing overexpressed Lin28a-GFP (Figure 5A, B, Supplementary Figure 4). The binding of 
Lin28a was significantly decreased by the competition of untagged pre-let-7a-1, but not the chimeric 
pre-let-7a-1/miR-16-TL (that does not bind Lin28a (44)), where the CTL of pre-let-7a-1 was replaced 
by the TL of miR-16 (Figure 5C, D). Notably, the Lin28a-GFP rings were significantly reduced by 
polyclonal anti-Lin28a antibody, compared to anti-HuR antibody (Figure 5E, F).
These results demonstrate that RP-CONA is a robust technique to screen for RNA-protein interaction 
modulators and that it could be used with various confocal image scanning platforms.
Pri-miR-7/HuR inhibitors identified by RP-CONA screening of a focused library.
MSI2 and HuR inhibit miR-7 biogenesis and the level of DROSHA cleavage (32). A range of 
compounds have been recognised to inhibit HuR or MSI2 binding to their target mRNAs (6). By 
collecting the commercially available HuR/MSI2 inhibitors, we built up a focused library and tested 
them using RP-CONA at 100 μM concentration (Figure 6A). The Z’ factor of the screen is 0.93, and 
the coefficients of variation (CVs) of the negative control (DMSO) and positive control (untagged 
pri-miR-7-1-CTL) equal to 1.75% and 0.96%, respectively (Figure 6B). As reported previously (35) 
OA did not show significant disruptive effects on pri-miR-7-1/HuR complex at 100 μM. Importantly, 
we identified quercetin, luteolin and gossypol as pri-miR-7-1/HuR inhibitors, which generated more 
than 50% inhibition at 100 μM concentration according to the relative mCherry/FITC signals 
compared to the DMSO control (Figure 6C). In summary, RP-CONA identified new potential 
inhibitors of pri-miR-7-1-CTL/HuR complexes. 
A small-scale prototype RP-CONA screen of pri-miR-7-1/HuR inhibitors 
In order to analyse RP-CONA’s ability to scale up and to establish the sensitivity of the method, we 
performed a small-scale prototype screen using an in-house library containing 54 FDA-approved 
drugs or natural products, together with 8 compounds from the previous focused screen (Figure 7A). 
Here, we applied quercetin as a positive control and DMSO as a negative control. The CVs of the 
negative and positive controls were 6.70% and 2.18%, respectively. Most compounds did not show 
significant stabilisation or destabilisation of the pri-miR-7-1-CTL/HuR complex. Additionally, we 
































































identified genistein as a new hit, albeit not as effective as quercetin or luteolin. To validate the active 
compounds identified in the primary screen, we tested them in a standard pull-down assay where pri-
miR-7-1-CTL was covalently linked to the beads (56). Importantly, this assay, unlike RP-CONA, 
only gives semi-quantitative readout. The western blot analysis of the HuR pull-down confirmed the 
strong disruptive effects of quercetin and luteolin (Figure 7B). Similar effects from DHTS, Ro, and 
genistein were also observed. Meanwhile, gossypol largely reduced pull-down of the RNA helicase 
DHX9, implying the effects of this compound are unspecific. Our most effective inhibitors quercetin 
and luteolin are close analogues (Figure 7C). We tested quercetin and luteolin in RP-CONA at a range 
of concentrations. The RP-CONA signals were reduced in a dose-dependent manner for both 
quercetin and luteolin, showing the half maximal inhibitory concentrations (IC50s) at 2.15±0.16 μM 
and 2.03±0.25 μM, respectively (Figure 7D). These observations indicate that RP-CONA primary 
hits were successfully validated using a classic biochemical method and further confirm quercetin 
and luteolin as the most promising inhibitors of the pri-miR-7-1/HuR complex.
Quercetin inhibits cellular α-Syn and upregulates miR-7
Subsequently, we tested quercetin and luteolin in HeLa cells at 20 μM concentration. Quercetin 
treated cells had a significantly reduced level of α-Syn protein, with a 1.5-fold upregulation of mature 
miR-7 level (Figure 8A-C). We found that quercetin induced pre-miR-7-1 but not pri-miR-7-1 levels 
more than 2-fold (Supplementary Figure 5A, B). The expression of DGCR8 and DICER were not 
significantly changed after quercetin treatment, albeit DROSHA levels were slightly upregulated 
(Supplementary Figure 5C). This suggests the amount of Microprocessor and DICER remained 
largely unaffected, and that quercetin rescues the inhibitive effect of HuR that blocks the pri-miR-7-
1 processing. Importantly, the quercetin-mediated dissociation of HuR/MSI2 with pri-miR-7-1 was 
confirmed by RP-SMS (RNA Pull-down SILAC Mass Spectrometry (37)) (Supplementary Figure 
5D). Interestingly, luteolin had no significant effect on α-Syn or miR-7, suggesting different 
bioavailability, dynamics or cellular metabolism when compared with quercetin (Figure 8A-C). 
To find out if quercetin acts through the miR-7/α-Syn pathway, we deleted the stem loop region of 
pri-miR-7-1 in the genome of HeLa cells, using CRISPR-Cas9 and generated miR-7-1+/- and miR-
7-1-/- cell lines (Supplementary Figure 6). However, quercetin could still inhibit the expression of α-
Syn, even though miR-7 was reduced by half or completely depleted (Figure 8D). Next, we tested 
these compounds in HuR KO HeLa cells generated by CRISPR-Cas9 (Supplementary Figure 2 A, B, 
D). Importantly, in these cells, quercetin did not affect the levels of α-Syn expression (Figure 8E, F). 
































































Intriguingly, in HeLa HuR KO cells the miR-7 levels were upregulated by 2 and 3-fold by quercetin 
and luteolin, respectively (Figure 8G). This suggests more complex network of miRNA regulation in 
the absence of HuR. Finally, we investigated the mRNA levels of α-Syn after quercetin treatment. 
Quercetin significantly reduced α-Syn mRNA by 50% in wildtype HeLa and miR-7 KO cells, while 
a less significant 20% inhibition was seen in HuR KO HeLa cells (Figure 8H). Thus, we conclude 
that the HuR-mediated activity of quercetin towards α-Syn is exerted at least partially at the mRNA 
level. In summary, in our cellular model quercetin downregulates α-Syn expression and this 
regulation is HuR-dependent.
Quercetin inhibits HuR binding to both pri-miR-7-1 and α-Syn mRNA in cells
The 3’-UTR of α-Syn mRNA bears AU-rich elements (AREs) that are common binding targets of 
HuR (57). To further explore the quercetin/HuR/α-Syn pathway, we performed an RNA 
immunoprecipitation (RIP) assay on quercetin-treated HeLa cells with overexpressed HuR. The HuR-
mediated immunoprecipitation of pri-miR-7-1 significantly decreased in the quercetin-treated cells 
(Figure 9A). We also observed a noticeable reduction of HuR-mediated immunoprecipitation of α-
Syn mRNA upon quercetin treatment (Figure 9B). Therefore, quercetin inhibits HuR binding to both 
pri-miR-7-1 and α-Syn mRNA in living cells. We then validated the α-Syn-ARE/HuR binding in RP-
CONA, and the interaction could be inhibited by quercetin at high concentrations (Figure 9C, D). 
Finally, quercetin reduced luciferase levels in our dual luciferase reporter assay with α-Syn mRNA 
3’-UTR coupled with Renilla luciferase (Figure 9E). The overexpression of HuR upregulated Renilla 
luciferase level by two-fold, which was reduced to the mock control levels upon quercetin treatment. 
Notably, the relative levels of the Renilla luciferase mRNA were not enhanced by HuR (Figure 9F), 
implying HuR induces the translation of α-Syn through the 3’-UTR, and this can be reversed by 
quercetin. In the stability assay, quercetin treatment only slightly destabilised the α-Syn mRNA in 
WT HeLa cells after actinomycin D treatment for 6 hours, while exerted no effects in the HuR KO 
cells (Figure 9G). In conclusion, quercetin interrupts the α-Syn-ARE/HuR interaction, suppressing 
the HuR-engaged α-Syn expression mainly at the translational level with some contribution from 
regulating mRNA levels. However, the contribution of quercetin-mediated induction of miR-7 
towards destabilisation of α-Syn mRNA could be still important in other cellular systems such as 
mature neurones.

































































α-Syn has become a popular target for investigational PD therapies, with RNA interference (RNAi) 
strategies focusing on α-Syn repression presently at preclinical stages (58). An shRNA therapeutic 
achieved a 35% knockdown of SNpc α-Syn, and showed protective effects in a PD rat model without 
notable toxicity (59). However, neuronal toxicity has been found in animal brains when another 
siRNA-induced α-Syn knockdown reached 90% (60,61). Therefore, the knockdown efficiency of α-
Syn-targeted RNAi needs to be tightly controlled within an appropriate range in order to reach a 
compromise of both safety and efficacy (61,62). MiRNAs, known as fine tuners of gene expression, 
buffer the expression network against environmental or genetic stress (63). Here we provide evidence 
that miR-7 is the most effective suppressor of α-Syn expression, among all potential α-Syn targeting 
miRs that are downregulated in PD (Figure 1). Therefore, fine-tuning α-Syn expression by elevating 
miR-7 level could provide a novel avenue for the development of PD therapy.
Previously we have shown that miR-7 biogenesis is inhibited through an interaction between the pri-
miR-7-1-CTL and HuR (32). The best elucidated miR post-transcriptional regulation is between let-
7 and Lin28 proteins. A range of screens targeting let-7/Lin28 have been carried out using 
fluorescence resonance energy transfer (FRET) or fluorescence polarisation (FP) methods, and some 
hits have shown promising anti-cancer properties by dissociating the RNA-protein interaction and 
upregulating let-7 levels (6). However, due to a lack of understanding of the interaction domains 
where pri-miR-7 binds HuR, it seems challenging to identify pri-miR-7-1/HuR inhibitors using 
similar approaches. To tackle this problem, we developed the RP-CONA technique that combines the 
RNA pull-down assay in human cell extracts with the CONA screening platform (37-39). 
The RNA pull-down assay captures proteins by on-bead RNA fragments from eukaryotic cell lysates 
(37). The application of cell extracts instead of purified protein allows the screening to take place in 
a more physiological environment and might help avoiding false positives that are not functional in 
vivo. Moreover, this technique removes the need of protein purification, making it an alternative 
solution to study RNA/protein binding events for those proteins with difficulty in purification. CONA 
is a previously established, sensitive and quantifiable on-bead imaging platform (64,65). The only 
known ligand targeting the RNA recognition motif-3 (RRM3) of HuR was identified by CONA from 
one-bead-one-compound libraries (66). Notably, using the RRM3 binder and CONA, an ATP-binding 
pocket was discovered in RRM3, which was not detected using conventional binding assays (66,67). 
CONA is also highly flexible, and it can be modified to monitor complex biological processes in real 
time, such as ubiquitination-related enzymatic activities and aggregation of α-Syn (38,40). A recent 
































































publication successfully identified protein binders from natural product extracts with CONA (41). 
Here, for the first time we applied CONA to study RNA-protein interactions by using a lysate-based 
screening strategy. We believe that this combination has a high potential for further exploitation in 
miniaturized drug screening. RP-CONA is a versatile technique that is not limited to monitor the pri-
miR-7/HuR activity. We have shown that RP-CONA is applicable in different RNA/protein 
complexes such as pre-let-7a-1/Lin28a (Figure 5), αSyn-ARE/HuR (Figure 9C) and TNFα-ARE/HuR 
(Supplementary Figure 7). This provides an alternative method to look for RNA-protein modulators 
in the environment of the mammalian cell extracts.
In order to look for pri-miR-7-1/HuR inhibitors, we started with a focused prototype screen. The 
library contained 8 compounds that were known to interfere with the RNA binding activities of HuR 
or MSI2, as both of the proteins are essential during the blockage of miR-7 biogenesis (6). We found 
half of the compounds resulting in more than 50% inhibition of RP-CONA signals (Figure 6). By 
integrating the focused library with a diverse in-house 54-compound library, we have shown that the 
former 4 compounds were still effective, and only one additional hit was discovered from the new 
library. The disruptive effects of these hits were confirmed in RP-CONA with a gradient of 
concentrations, and the IC50s of the most effective hits quercetin and luteolin were around 2 μM. We 
subsequently validated the primary hits using the standard RNA pull-down assay followed by western 
blot, and managed to exclude the unspecific disruptor gossypol, which also interrupted the binding 
of the reference protein DHX9 (Figure 7). Previously, quercetin was recognized as a pre-let-
7g/Lin28a inhibitor with less than 2.5 µM IC50s in EMSA and a fluorescence intensity‐based binding 
assay (68). However, in our hands 100 µM of quercetin only mildly inhibited Lin28a binding to pre-
let-7a-1-CTL in RP-CONA (Supplementary Figure 8), suggesting that quercetin is more effective 
towards pri-miR-7-1/HuR in cell extracts.
Quercetin has been shown to inhibit the interaction between HuR and TNF-α mRNA, with an IC50 of 
1.4 μM in RNA electrophoretic mobility gel shift assay (EMSA) (42). Luteolin binds the RRM1 of 
MSI1, the paralogue of MSI2, with a dissociation constant (Kd) of around 3 μM (69). Interestingly, 
luteolin is a close analogue of quercetin. In an FP assay, both luteolin and quercetin interrupted MSI1-
RRM1 binding with a short RNA motif at micromolar and millimolar IC50s, respectively (69). These 
findings imply that quercetin is likely to be a dual-inhibitor of both HuR and MSI2, marking it a 
strong candidate as an miR-7 enhancer. As expected, we identified a 1.5-fold upregulation of mature 
miR-7 in HeLa cells after 20 μM of quercetin treatment (Figure 8C). This is consistent with what we 
saw when HuR or MSI2 or both were knocked down (32). At the same time, a significant 
downregulation of α-Syn expression was observed (Figure 8A, B). It has been reported that quercetin 
































































exerts neuroprotective effects in different cell or animal models of PD (70-72). Moreover, oxidized 
quercetin can prevent α-Syn fibrillization in vitro (73). Interestingly, in neuron-like PC12 cells α-Syn 
expression was induced by 50 to 500 μM of quercetin, albeit reduced when quercetin reached 1 mM 
(74). These discrepancies may be attributed to the selection of cell lines. We also used quercetin to 
treat human neuroblastoma SH-SY5Y and neuron-like mouse embryonic carcinoma P19 cell lines. 
The reduction of α-Syn expression was notable but was less significant than that observed in HeLa 
cells (Supplementary Figure 5E). As mentioned above, HeLa cells were selected due to its abundant 
expression of α-Syn, so the reduced α-Syn level could have been easily detected. Additionally, 
luteolin did not show similar effects of miR-7 induction or α-Syn inhibition as its analogue quercetin 
(Figure 8A-C). This suggests quercetin and luteolin may present different bioavailability in living 
cells, despite their similar performance in RP-CONA. This is reminiscent of the evidence that 
quercetin was readily incorporated into cells, while another close flavonoid analogue myrincetin had 
poor cellular uptake (75). Collectively, we present the first report of quercetin as a miR-7 enhancer 
and α-Syn inhibitor at low concentrations.
We hypothesized that quercetin inhibits α-Syn through the pri-miR-7-1/HuR pathway. However, we 
found similar inhibitive effects of quercetin in miR-7 KO HeLa cells, which means the upregulated 
miR-7 is not the major contributor of α-Syn suppression (Figure 8D). Indeed, quercetin has reduced 
α-Syn expression by around 60% in wildtype HeLa cells, and it would require more than 1,000-fold 
miR-7 upregulation to achieve a similar extent of α-Syn inhibition in the same cell line (Figure 1, 
Supplementary Figure 1A). Crucially, we found that α-Syn remained unchanged upon quercetin 
treatment when HuR was absent (Figure 8E, F). Nevertheless, the upregulation of miR-7 was still 
observed (Figure 8G). These results strongly imply that HuR is an essential part in the quercetin-
mediated inhibition of α-Syn levels, although it seems not connected to the regulation of miR-7 
biogenesis in our cellular system. Moreover, the biogenesis of miR-7 is also regulated by some other 
protein complexes, including SF2/ASF, NF45-NF90 and QKI (76-78). Therefore, the removal of HuR 
may allow alternative miR-7 regulation pathways to take over. This may explain why luteolin did not 
affect miR-7 level in wildtype HeLa, but significantly induced miR-7 in HuR KO HeLa cells.
HuR is known to stabilise target mRNAs through the AREs in their 3’-UTRs (57). A recent study 
indicates that HuR interacts with the 3’-UTR of α-Syn mRNA and increases its stability in an mRNA 
decay assay in HeLa cells, although the knockdown of HuR only shows mild inhibition on α-Syn 
expression. Importantly, the stabilisation seems to be independent of miR-7 (79). In our study, 
quercetin decreased α-Syn mRNA, and it was HuR-dependent. At the same time, in HeLa cells, the 
pri-miR-7-1/HuR pathway is not a major contributor of quercetin-mediated α-Syn inhibition (Figure 
































































8H). Using an immunoprecipitation assay, we found that quercetin inhibited HuR from interacting 
with pri-miR-7-1 in cells, and the effect towards α-Syn mRNA was milder (Figure 9A). Consistently, 
in RP-CONA, quercetin was effective at 20 µM on inhibiting pri-miR-7-1-CTL/HuR (Figure 7D), 
but it required 200 µM of quercetin to interrupt α-Syn-ARE/HuR (Figure 9D), as well as TNFα-
ARE/HuR (Supplementary Figure 7). This suggests higher affinity between the α-Syn-ARE/HuR 
interaction than pri-miR-7-1-CTL/HuR, or different acting mechanisms of quercetin. Our luciferase 
assays showed that the overexpressed HuR enhanced the expression of luciferase with α-Syn mRNA 
3’-UTR at translational level, which could be reversed by quercetin (Figure 9E, F). In an actinomycin 
D-based stability assay, endogenous HuR only slightly enhanced the stability of α-Syn mRNA, which 
could be eliminated by quercetin (Figure 9G). However, this assay may not be the best model to study 
the effects of quercetin on α-Syn mRNA stability, and the treatment time of 12 hours (limited by 
actinomycin D toxicity) could be too short to induce significant effects. As there is clear evidence of 
quercetin reducing α-Syn mRNA levels after 48-hour treatment (Figure 8H), we cannot rule out the 
possibility that quercetin reduces steady state levels of α-Syn mRNA by regulating other post-
transcriptional processes including splicing, export or localisation. These assumptions are supported 
by some evidences with HuR regulating mRNA alternative splicing (80), as well as alternative 
polyadenylation (81). Based on our results we conclude that quercetin interrupts HuR binding with 
both pri-miR-7-1 and α-Syn mRNA, promoting miR-7 biogenesis, inhibiting α-Syn translation, and 
reducing α-Syn transcripts levels. All of these together contribute to the strong repression on α-Syn 
expression by quercetin.
To summarise, we developed an on-bead screening platform, RP-CONA, for the identification of 
RNA-protein interaction modulators. We employed RP-CONA to look for inhibitors of pri-miR-7-
1/HuR interactions. The most potent hit quercetin was proven to be a miR-7 enhancer as well as an 
α-Syn inhibitor, implying a potential as PD therapeutic. The mechanism of quercetin-mediated 
inhibition of α-Syn is HuR-dependent. Additionally, quercetin displayed positive effects on miR-7 
levels, but the achieved upregulation was too small to directly affect α-Syn. Further work needs to be 
focused on the evaluation of quercetin in PD models, especially in the context of mature neurones as 
well as α-Syn overproduction and accumulation. In the meantime, the RP-CONA screening method 
can be used to identify more potent and specific miR-7 enhancers and α-Syn inhibitors. In summary, 
our work delivers a new platform for the identification of RNA-protein interaction modulators, and 
highlights quercetin as a potential hit compound towards treatment of PD.
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CTL conserved terminal loop





EMSA electrophoretic mobility gel shift assay
FITC fluorescein isothiocyanate
FP fluorescence polarisation
FRET fluorescence resonance energy transfer
































































HCS High Content Screening




MSI2 Musashi RNA binding protein 2
OA oleic acid
PBS phosphate-buffered saline
PCR polymerase chain reaction
PD Parkinson’s disease
PMSF phenylmethanesulfonylfluoride
pre-miR, pre-miRNA precursor microRNA
pri-miR, pri-miRNA primary microRNA
qRT-PCR real-time quantitative PCR
RBP RNA binding protein
RIP RNA immunoprecipitation
RNA ribonucleic acid

































































RP-CONA RNA Pull-Down Confocal Nanoscanning
RP-SMS
RRM
RNA Pull-Down SILAC Mass Spectrometry
RNA recognition motif
SD standard deviation
SEM standard error mean
shRNA short hairpin RNA
siRNA small interfering RNA
SNpc substantia nigra pars compacta
TNF-α tumour necrosis factor alpha
α-Syn α-Synuclein
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Figure 1. MiR-7 is a major suppressor of α-Syn expression. (A). Predicted binding sites of miRs on 
the 3’-UTR of α-Syn mRNA (~2,500 bp). The putative binding sites of different miRs are annotated 
at the approximate positions on the α-Syn mRNA 3’-UTR. These sites were predicted by TargetScan 
(47) or provided by miRTarBase (48). Sites highlighted by the red arrows were previously reported. 
(B). MiR-7 inhibited luminescence of a dual luciferase reporter bearing the gene of α-Syn mRNA 3’-
UTR downstream the Renilla luciferase gene. Equal amount of each pCG-pri-miR plasmid was co-
transfected with the luciferase reporter. PCG-pri-miR-9 was tested as a negative control. Luciferase 
levels were recorded 48 hours after transfection. Mean Renilla/firefly values and SEM from 6 
independent repeats are shown. (C). Single-nucleotide mutation of miR-7 binding site inactivated the 
inhibitive effects of miR-7. The nucleotide on the 3rd position of miR-7 targeted seed regions on α-
Syn mRNA 3’-UTR gene was mutated individually. The mutants were numbered according to the 
binding sites from 5’ to 3’ of α-Syn mRNA 3’-UTR. Luciferase levels were measured 48 hours after 
the co-transfection of pCG-pri-miR-7-1 plasmids with reporters bearing wildtype or mutated α-Syn 
mRNA 3’-UTR gene. The luciferase levels were relative to co-transfection of pCG-pri-miR-9 with 
wildtype reporter. Mean Renilla/Firefly values and SEM from three independent repeats are shown. 
(D, E). α-Syn expression was inhibited by upregulated miR-7. 1: Mock HeLa cells without DNA 
transfected. 2-6: An increasing amount of pCG-pri-miR-7-1 was transfected into HeLa cells. The 
expression of α-Syn and α-tubulin were detected by western blot 48 hours after transfection. Relative 
α-Syn/α-tubulin levels were normalised to mock. Mean values and SEM from three independent 
repeats are shown. Statistically significant differences compared to mock were interpreted by SPSS 
one-way ANOVA, with post hoc LSD test, *P<0.05, **P<0.01, ***P<0.001. 
Figure 2. The working scheme of RP-CONA. RNA Pull-Down (RP): 5’-FITC-pri-miR-7-1-CTL-
biotin-3’ is coupled to streptavidin coated agarose beads. Cell lysates are extracted from HuR KO 
HEK293T cells overexpressing mCherry-HuR and treated with small molecules. The RNA-coupled 
beads are incubated with cell lysates to pull-down mCherry-HuR. Confocal Nanoscanning (CONA): 
Beads are imaged using a confocal image scanning platform. On-bead FITC-pri-miR-7-1-CTL and 
mCherry-HuR are detected with high sensitivity as fluorescent rings/halos on the outer shell of bead 
in corresponding detection channels. Inhibitors are able to attenuate the mCherry fluorescence 
without affecting FITC signals. Analysis: The fluorescent rings are detected in ImageJ. Three 
measurements are taken across each ring and generate the fluorescent intensity profiles to obtain 
arbitrary intensity values.
































































Figure 3. Optimisation of RP-CONA method in the Opera HCS. (A). A diagram illustrating the 
interaction between FITC-pri-miR-7-1-CTL and mCherry-HuR. (B). Beads images of blank beads; 
blank beads incubated with cell lysates containing mCherry-HuR; FITC-pri-miR-7-1-CTL-beads 
incubated in lysates-free buffer; and FITC-pri-miR-7-1-CTL-beads after mCherry-HuR pulldown. (C, 
D). mCherry/FITC signals were reduced by untagged pri-miR-7-1-CTL. Cell lysates containing 
mCherry-HuR were treated with an increased concentration of untagged pri-miR-7-1-CTL before 
pull-down. (E, F). mCherry/FITC signals were reduced by a pri-miR-7-1/HuR inhibitor. Cell lysates 
containing mCherry-HuR were treated with DMSO, or an increased concentration of OA before pull-
down. All values were obtained from three technical repeats. Mean mCherry/FITC ring intensities 
and SD between triplicates are shown. Statistically significant differences compared to 0 μM 
untagged pri-miR-7-1 or DMSO were interpreted by SPSS independent sample t-test, **** P<0.0001.
Figure 4. RP-CONA detects the specific interaction of pri-miR-7-1-CTL/HuR. (A) A diagram 
illustrating that mCherry-HuR interacts with FITC-pri-miR-7-1-CTL, but not FITC-pri-miR-7-1/30a-
TL. (B). mCherry-HuR pull-down by beads coupled with 40 pmol of FITC-pri-miR-7-1-CTL or 
FITC-pri-miR-7-1/30a-TL. (C). Pri-miR-7-1-CTL binds mCherry-HuR but not mCherry. FITC-pri-
miR-7-1-CTL beads were incubated with cell extracts containing 300 nM mCherry-HuR or mCherry. 
(D, E). mCherry/FITC signals were reduced by anti-HuR antibody. Cell extracts containing 300 nM 
mCherry-HuR were pre-incubated with 2 µl (+) or 4 µl (++) of anti-Lin28a antibody (control) or anti-
HuR antibody prior pulldown by FITC-pri-miR-7-1-CTL-beads. Mean mCherry/FITC ring intensities 
and SD between triplicates are shown. Statistically significant differences compared to anti-Lin28a 
antibody treated samples were interpreted by SPSS independent sample t-test, ** P<0.01, *** 
P<0.001.
Figure 5. RP-CONA detects the specific interaction of pre-let-7a-1-CTL/Lin28a. (A). A diagram 
illustrating the interaction between Cy5-pre-let-7a-1-CTL and Lin28a-GFP. (B). Beads images of 
Cy5-pre-let7a-1-CTL-beads incubated in lysates-free buffer; blank beads incubated with cell lysates 
containing Lin28a-GFP; Cy5-pre-let7a-1-CTL-beads incubated with cell lysates containing Lin28a-
GFP; and Cy5-pre-let-7a-1-CTL-beads incubated with cell lysates containing GFP. (C, D). GFP/Cy5 
signals were reduced by unlabelled pre-let-7a-1. Cell extracts containing 300 nM of GFP-Lin28a 
were treated with 80 pmol of pre-let-7a-1 or pre-let-7a-1/miR-16-TL, prior to pull-down with Cy5-
pre-let7a-1-CTL-beads. (E, F). GFP/Cy5 signals were reduced by anti-Lin28a antibody. Cell extracts 
containing 300 nM Lin28a-GFP were pre-incubated with 2 µl (+) or 4 µl (++) of anti-HuR antibody 
(control) or anti-Lin28a antibody prior pulldown by Cy5-pre-let-7a-1-CTL-beads. Mean GFP/Cy5 
































































ring intensities and SD between triplicates are shown. Statistically significant differences compared 
to HuR antibody treated samples were interpreted by SPSS independent sample t-test, *** P<0.001, 
****P<0.0001. 
Figure 6. RP-CONA identified pri-miR-7-1/HuR inhibitors from a focused library. (A) Cell lysates 
containing mCherry-HuR were treated with DMSO, 50 μM of untagged pri-miR-7-1-CTL or 100 μM 
of compounds before pulldown. Beads images taken in ImageXpress. (B) Relative mCherry/FITC 
ring intensity mean and SD between the beads in each well after compound treatment are shown. 
DMSO (RP-CONA ratio: 0.932±0.016, CV: 1.75%, n=5) served as a negative control while 50 μM 
of untagged pri-miR-7-1-CTL (RP-CONA ratio: 0.124±0.001, CV: 0.96%, n=5) served as a positive 
control. Z’ = 0.93. Black lines: DMSO mean ± 3×SD between 5 repeated wells. Red lines: untagged 
pri-miR-7-1-CTL mean ± 3×SD between 5 repeated wells. At least 400 beads were included in each 
control analysis. (C). Inhibition of RP-CONA signals compared to DMSO. The percentage inhibition 
of compounds relative to DMSO mean are shown. The SD of relative inhibitions between the beads 
in each well after compound treatment are shown. 
Figure 7. Identification and validation of pri-miR-7-1/HuR inhibitors from an enlarged library. (A) 
A small-scale prototype RP-CONA screen to test the disruptive effects of 61 compounds (54 from an 
in-house library varied from 1 to 100 μM, and 7 from the previous identified HuR or MSI2 inhibitors 
at 100 μM) on pri-miR-7-1/HuR. Relative mCherry/FITC ring intensity mean and SD between the 
beads in each well after compound treatment are shown. DMSO (RP-CONA ratio: 1.009±0.067, CV: 
6.70%, n=6) served as a negative control while 100 μM of quercetin (RP-CONA ratio: 0.288±0.006, 
CV: 2.18%, n=6) served as a positive control. Z’ = 0.69. Black lines: DMSO mean ± 3×SD between 
6 repeated wells. Red lines: quercetin mean ± 3×SD between 6 repeated wells. At least 500 beads 
were included in each control analysis. Compounds generating larger than 40% (6 times CV of 
negative controls) inhibition are annotated. (B) Disruption of endogenous HuR pulled down by pri-
miR-7-1-CTL. Pri-miR-7-1-CTL was covalently linked to agarose beads. HeLa extracts were treated 
with DMSO or 100 μM of each compound prior to pull-down. HuR and DHX9 in the pull-down 
components were detected by western blot. 1: Input. Unbound proteins in the lysates after pulldown. 
2: Proteins pulled down by beads without RNA. 3-9: Proteins pulled down by pri-miR-7-1-CTL-
beads after compound treatment. (C) Chemical structures of quercetin and luteolin. (D) Quercetin 
and luteolin disrupted pri-miR-7/HuR in a dose-dependent manner in RP-CONA. Increased 
concentrations of quercetin and luteolin were tested in RP-CONA. Relative mCherry/FITC ring 
intensity mean and SD between triplicated wells after compound treatment are shown. The RP-CONA 
signals were curve fitted by non-linear regression-four parameter [inhibitor] versus response, and 
































































IC50s were determined with the 4-parameter equation in GraFit v7.0.3 (Erithacus Software Limited) 
(40). The IC50s of quercetin and luteolin were 2.15±0.16 μM and 2.03±0.25 μM, respectively.
Figure 8. Quercetin inhibits cellular α-Syn and upregulates miR-7. (A, B). Quercetin significantly 
downregulates α-Syn expression in HeLa cells. HeLa cells were treated with 1: DMSO, 2: 20 μM of 
quercetin or 3: luteolin and harvested 48 hours after treatment. Levels of α-Syn and α-tubulin were 
detected by western blot. Mean α-Syn/α-tubulin and SEM from three independent repeats are shown. 
(C). Quercetin upregulates cellular miR-7 level by 1.5-fold. HeLa cells were treated with DMSO, 20 
μM of quercetin or luteolin and harvested 48 hours after treatment. Mature miR-7 and miR-181d 
(housekeeping miR control) levels were determined by qRT-PCR. Mean miR-7/miR-181d and SEM 
from three independent repeats are shown. (D) Quercetin reduces α-Syn expression in a miR-7-
independent pathway. HeLa miR-7-1 KO H3 (miR-7-1-/-), B4 (miR-7-1-/-) and C3 (miR-7-1+/-) were 
treated with 1, 4, 7: DMSO, 2, 5, 8: 20 μM of quercetin, or 3, 6, 9: luteolin for 48 hours. Expression 
of α-Syn and α-tubulin were detected by western blot. (E, F) Quercetin reduces α-Syn expression in 
an HuR-dependent manner. HuR KO HeLa cells were treated with 1: DMSO, 2: 20 μM of quercetin 
or 3: luteolin and harvested 48 hours after treatment. Levels of α-Syn and α-tubulin were detected by 
western blot. Mean α-Syn/α-tubulin and SEM from three independent repeats are shown. (G) 
Quercetin and luteolin upregulate cellular miR-7 level in HuR KO HeLa. HuR KO HeLa cells were 
treated with DMSO, 20 μM of quercetin or luteolin and harvested 48 hours after treatment. Mature 
miR-7 and miR-181d levels were determined by qRT-PCR. Mean miR-7/miR-181d and SEM from 
three independent repeats are shown. (H) Quercetin downregulates α-Syn mRNA level in an HuR-
dependent manner. Wildtype, HuR KO and miR-7-1 KO (H3, B4 and C3) HeLa were treated with 
DMSO or 20 μM of quercetin and harvested 48 hours after treatment. α-Syn and GAPDH mRNA 
levels were determined by qRT-PCR. Mean α-Syn/GAPDH and SEM from three independent repeats 
are shown. Statistically significant differences compared to DMSO, or between quercetin treated cells 
were interpreted by SPSS independent sample t-test, * P<0.05, ** P<0.01, *** P<0.001, **** 
P<0.0001.
Figure 9. Quercetin interrupts HuR from binding to pri-miR-7-1 and α-Syn mRNA in cells. (A, B). 
Quercetin reduced efficiency of pri-miR-7-1 (A) and α-Syn mRNA (B) RIP with HuR in HeLa cells. 
Mock or HuR-overexpressed HuR KO HeLa cells were treated with DMSO or 20 μM of quercetin 
and harvested 48 hours after treatment. HuR bound RNAs from cell lysates were immunoprecipitated 
by anti-HuR antibody-coated beads and quantified by qRT-PCR. RNA levels were normalised to 
DMSO treated mock samples. Mean relative RNA levels and SEM from three independent repeats 
































































are shown. Statistical tests were interpreted by SPSS independent sample t-test, ** P<0.01. (C, D). 
Quercetin inhibits α-Syn-ARE/HuR binding in RP-CONA. A diagram illustrates the interaction 
between FITC-α-Syn-ARE with mCherry-HuR. Cell extracts containing 50 nM of mCherry-HuR 
were pre-incubated with an increased concentration of quercetin, prior pull-down by FITC-α-Syn-
ARE-beads. Mean mCherry/FITC ring intensities and SD between triplicates are shown. Statistically 
significant differences compared to DMSO were interpreted by SPSS independent sample t-test, * 
P<0.05, ** P<0.01. (E, F). Quercetin inhibits the HuR-induced expression of luciferase bearing the 
3’UTR of α-Syn mRNA. Mock or HuR overexpressed HeLa cells were treated with DMSO or 20 µM 
of quercetin, and transfected with the dual luciferase reporter carrying α-Syn-3’UTR downstream the 
Renilla luciferase gene. Mean luminescence levels (E) and mRNA levels (F) of Renilla/firefly 
luciferases, and SEM from 3 independent repeats are shown. Statistically significant differences 
between groups, or compared to mock DMSO were interpreted by SPSS independent sample t-test, 
* P<0.05, ** P<0.01, *** P<0.001. (G). The effects of quercetin on α-Syn mRNA decay. Wildtype 
and HuR KO HeLa cells were treated with DMSO or 20 µM of quercetin, supplemented with 10 
µg/mL of actinomycin D for 0, 6 and 12 hours respectively. α-Syn mRNA and 18S levels were 
determined by qRT-PCR. Mean α-Syn/18S and SEM from three independent repeats are shown.
































































MiR-7 is a major suppressor of α-Syn expression 
































































The working scheme of RP-CONA 
































































Optimisation of RP-CONA method in the Opera HCS 
































































RP-CONA detects the specific interaction of pri-miR-7-1-CTL/HuR 
































































RP-CONA detects the specific interaction of pre-let-7a-1-CTL/Lin28a 
































































RP-CONA identified pri-miR-7-1/HuR inhibitors from a focused library 
































































Identification and validation of pri-miR-7-1/HuR inhibitors from an enlarged library 
































































Quercetin inhibits cellular α-Syn and upregulates miR-7 
































































Quercetin interrupts HuR from binding to pri-miR-7-1 and α-Syn mRNA in cells 

































































































































Supplementary Figure 1. MiR-7 is a major suppressor of α-Syn expression. (A) Upregulation of 
miRNAs after overexpression. Mature miR-7, miR-153 and miR-133b levels from HeLa cells 
transfected with increasing amount of corresponding pCG plasmids were determined by qRT-PCR 
and normalised to mock (no DNA transfected). (B) Single-nucleotide mutation of miR-133b and miR-
153 binding site upregulated luciferase levels. The nucleotide on the 3rd position of miR-153 and 
miR-133b targeted seed regions on α-Syn mRNA 3’-UTR gene was mutated individually. The 
mutants were numbered according to the binding sites from 5’ to 3’ of α-Syn mRNA 3’-UTR. 
Luciferase levels were measured 48 hours after the co-transfection of pCG-pri-miR-133b or pCG-
pri-miR-153-1 plasmids with reporters bearing wildtype or mutated α-Syn mRNA 3’-UTR gene. The 
luciferase levels were relative to co-transfection of pCG-pri-miR-9 with wildtype reporter (mock). 
Mean Renilla/firefly values and SEM from three independent repeats are shown. Statistically 
significant differences compared to mock were interpreted by SPSS one-way ANOVA, with post hoc 
LSD test, **P<0.01, ***P<0.001, ****P<0.0001. (C) MiR-153 and miR-133b exert mild inhibition 
on α-Syn expression.1: Mock HeLa cells without DNA transfected. 2-6: Increased amount of pCG-
pri-miR-153-1 wase transfected into HeLa cells. 7-11: Increased amount of pCG-pri-miR-133b was 
transfected into HeLa cells. The expression of α-Syn and α-tubulin were detected by western blot 48 
hours after transfection. 

































































Supplementary Figure 2. HuR knockout and overexpression. (A) Design of HuR knockout by 
CRISPR-Cas9. Human HuR exon2 is shown in orange. A pair of guide RNAs are shown in blue 
arrows. PAM sequences are presented. (B) Sequence alignment of HuR knockouts. The DNA 
sequences of HuR exon2 of HEK293T and HeLa knockouts were aligned to the wildtype sequence 
in Clone Manager 10. Termination signals resulting from frame shifts are annotated by red stars. (C) 
Validation of HuR knockout and mCherry-HuR overexpression in HEK293T cells. The endogenous 
HuR and overexpressed mCherry-HuR levels were tested against HuR antibody in western blot. 
DHX9 was tested as a reference protein. 1: Wildtype HEK293T. 2: HuR KO HEK293T. 3: HuR KO 
HEK293T transfected with pJW99-HuR. (D) Validation of HuR knockout in HeLa cells. The HuR 
levels were tested against HuR antibody in western blot. DHX9 was tested as a reference protein. 1: 
Wildtype HeLa. 2: HuR KO HeLa. 

































































Supplementary Figure 3. Basic responses of RP-CONA in ImageXpress. (A) A diagram illustrating 
the interaction between FITC-pri-miR-7-1-CTL and mCherry-HuR. (B) Beads images of blank 
beads; blank beads incubated with cell lysates containing mCherry-HuR; FITC-pri-miR-7-1-CTL-































































beads incubated in lysates-free buffer; and FITC-pri-miR-7-1-CTL-beads after mCherry-HuR 
pulldown. (C- E) RP-CONA senses the increase of mCherry-HuR. FITC-pri-miR-7-CTL-beads were 
incubated with cell lysates containing an increased concentration of mCherry-HuR. All the 
quantifications were obtained from three technical repeats. Mean mCherry/FITC ring intensities and 
maximum SD between the beads in each well (D), or SD between triplicates (E) are shown. 

































































Supplementary Figure 4. The working scheme of RP-CONA targeting let-7/Lin28a. RNA Pull-
down (RP): 5’-Cy5-pre-let-7a-1-CTL-biotin-3’ is coupled to streptavidin coated agarose beads. Cell 
lysates are extracted from wildtype HEK293T cell overexpressing Lin28a-GFP and treated with small 
molecules. The RNA-coupled beads are incubated with cell lysates to pull-down Lin28a-GFP. 
Confocal Nanoscanning (CONA): Beads are imaged using a confocal image scanning platform. On-
bead Cy5-pre-let-7a-1-CTL and Lin28a-GFP are detected with high sensitivity as fluorescent 
rings/halos on the outer shell of bead in corresponding detection channels. Inhibitors are able to 
attenuate the GFP fluorescence without affecting Cy5 signals. Analysis: The fluorescent rings are 
detected in imageJ. Three measurements are taken across each ring and generate the fluorescent 
intensity profiles to obtain arbitrary intensity values.
 

































































Supplementary Figure 5. Quercetin induces miR-7 biogenesis while inhibiting α-Syn expression. 
(A, B). Quercetin induces pri-miR-7 processing into pre-miR-7. Wildtype HeLa cells were treated 
with DMSO or 20 μM of quercetin and harvested 48 hours after treatment. Pri-miR-7-1 (A) and pre-
miR-7-1 levels (B) were determined by qRT-PCR. Mean pri-miR-7-1/GAPDH, pre-miR-7-1/pre-































































miR-181d and SEM from three independent repeats are shown. Statistically significant differences 
compared to DMSO were interpreted by SPSS independent sample t-test, ** P<0.01. (C). The effects 
of quercetin on the machinery of miRNA biogenesis. Wildtype HeLa cells were treated with 1: 
DMSO, 2: 20 μM of quercetin and harvested 48 hours after treatment. Levels of DICER, DROSHA, 
DGCR8 and α-tubulin were detected by western blot. (D). Quercetin inhibits HuR and MSI2 binding 
to pri-miR-7. RNA pull-down-SILAC mass spectrometry was performed using heavy HeLa extracts 
(13C-arginine and 2D-lysine) treated with 100 µM quercetin, and light HeLa extracts (no labelling) 
treated with DMSO. The experiment was repeated twice. Identified peptides with intensities larger 
than 1×106 are shown in blue dots. The corresponding normalised relative heavy/light intensity ratios 
are shown. Proteins with H/L ratios less than 0.5 were considered as enriched in light pull-down 
components. HuR and MSI2 are highlighted with red dots. (E). Quercetin downregulates α-Syn 
expression in neuron-like cells. SH-SY5Y cells were treated with 1: DMSO, 2: 20 μM of quercetin 
or 3: luteolin and harvested 48 hours after treatment. P19 cells were differentiated by retinoic acid 
cells. On the Day 17 of differentiation, the cells were treated with 4: DMSO, 5: 20 μM of quercetin 
or 6: luteolin and harvested 48 hours after treatment. Levels of α-Syn and α-tubulin were detected by 
western blot. The experiments were repeated for three times.
 
 

































































Supplementary Figure 6. MiR-7-1 knockout by CRISPR-Cas9. (A) Design of miR-7-1 knockout by 
CRISPR-Cas9. Human pri-miR-7-1 stem loop sequence is shown in orange. Other regions are in grey. 
A pair of guide RNAs flanking the pri-miR-7-1 stem loop gene are shown in blue arrows. PAM 
sequences are presented. (B) Sequence alignment of miR-7-1 knockouts. Sequencing results of miR-
7-1 knockouts were aligned to the same region of wildtype HeLa gene in Clone Manager 10. Regions 
originally encoding pri-miR-7-1 stem loop are indicated. B4 is a miR-7-1-/- as the miR-7-1 stem loop 
was deleted in both alleles. C3 is a miR-7-1+/- as miR-7-1 was deleted in one allele while the other 
allele is intact. H3 has miR-7-1 deleted in one allele. The other allele, however, the miR-7-1 stem 
loop was re-assembled in an opposite orientation. Therefore, H3 is a miR-7-1-/-. (C) Genotyping and 
characterisation of miR-7-1 KO HeLa. Genomic DNA was PCR amplified using a pair of primers 
flanking pri-miR-7-1 stem loop. The deleted stem loop region was expected to be around 200 bp. 
Bands around 700 bp represent potential KO. (D) MiR-7 level of miR-7-1 KO HeLa. Mature miR-7 
and miR-181d levels of wildtype HeLa or miR-7-1 knockouts were determined by qRT-PCR. 
 
































































Supplementary Figure 7. Quercetin inhibits pre-let-7a-1/Lin28a interaction in RP-CONA (A). A 
diagram illustrating the interaction between Cy5-pre-let7a-1-CTL and Lin28a-GFP. (B, C). Cell 
lysates containing 300 nM of GFP-Lin28a were treated with 100 µM of quercetin, prior to pull-down 
by Cy5-pre-let7a-1-CTL-beads. Mean GFP/Cy5 ring intensities and SD between triplicates are 
shown. Statistically significant differences compared to HuR antibody treated samples were 
interpreted by SPSS independent sample t-test, ** P<0.01. 
































































Supplementary Figure 8. Quercetin inhibits TNFα-ARE/HuR in RP-CONA. (A). A diagram 
illustrates the interaction between FITC-TNFα-ARE with mCherry-HuR. (B, C). Cell extracts 
containing 50 nM of mCherry-HuR were pre-incubated with an increased concentration of quercetin, 
prior pull-down by FITC-TNFα-ARE-beads. Mean mCherry/FITC ring intensities and SD between 
triplicates are shown. Statistically significant differences compared to DMSO were interpreted by 
SPSS independent sample t-test, ** P<0.01, ***P<0.001.
































































Quantification of pri and pre-miRs 
Total RNA was treated by TURBOTM DNase (Thermo) to remove contaminant DNA. Pri-miRs were 
quantified by qRT-PCR with primers upstream the stem-loop structures, using the GoTaq® 1-Step 
RT-qPCR System (Promega). To test pre-miRs, total RNA was fractionated using a 6% Urea-PAGE 
gel. RNAs between the bromophenol blue (26 nt) and xylene cyanol (106 nt) dye were purified to 
remove pri and mature miRs. The purified RNAs were reversed transcribed following the instructions 
of the miScript II RT Kit for pre-miR. Then pre-miRs were quantified following the instructions of 
the SYBR Green PCR Kit (QIAGEN) using mature miR primers and the universal reverse primer 
provided. 
RNA pull-down-SILAC mass spectrometry (RP-SMS) 
RP-SMS was performed according to our previous published method (1). Heavy HeLa extracts (13C-
labelled arginine and 2D-labelled lysine) were treated with 100 µM quercetin, and light HeLa extracts 
(no labelling) were treated with equal volume of DMSO. Both cell extracts were incubated with pri-
miR-7-1-CTL-linked beads, respectively. The pull-down components from heavy and light extracts 
were combined during the last beads washing and loaded onto an SDS-PAGE gel. The mass 



























































































1. Choudhury, N.R. and Michlewski, G. (2018) Quantitative identification of proteins that influence 
miRNA biogenesis by RNA pull-down-SILAC mass spectrometry (RP-SMS). Methods. 
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